RxDoctor Payments Data

Alla Goldberg, DO

Nephrology · Flushing, NYNPI 1467698480

Payments from drug & device makers

$2,944in general payments, 2019–2025

Across 113 payments — averaging $26.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$744
  • Amgen$599
  • Vifor Pharma, Inc.$420
  • Aurinia Pharma U.S., Inc.$154
  • Fresenius USA Marketing, Inc.$149
  • Otsuka America Pharmaceutical, Inc.$141
  • plus $737 from 11 others

What the payments were for

  • Food & beverage$2,87598%
  • Education$692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,944 in reported general payments places this provider in the 70th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$211,993
Medicare patients
219
Services billed
1,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate38$66,614
VelphoroSucroferric Oxyhydroxide11$55,159
XphozahTenapanor Hcl15$42,296
LokelmaSodium Zirconium Cyclosilicate21$20,121
ProsolParenteral Amino Acid 20% No.145$7,713
Calcium Acetate47$5,168
Sevelamer Carbonate28$4,685
Midodrine Hcl19$765
Amlodipine Besylate99$570
Hydralazine Hcl42$464
Metolazone12$409
Losartan Potassium62$337
Metoprolol Succinate26$325
Carvedilol53$278
Albuterol Sulfate HfaAlbuterol Sulfate12$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$95$66,61438 claims
Fresenius USA Marketing, Inc.Velphoro$149$55,15911 claims
AstraZenecaLokelma$744$20,12121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 935 nephrology providers in New York.

Other nephrology in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →